Abstract
The prevalence of diabetes mellitus is increasing worldwide at an alarming rate due to population growth, obesity, sedentary lifestyle and aging. Consequently, diabetic microvascular complications (retinopathy and nephropathy) and macrovascular complications (coronary heart disease, peripheral arterial disease and cerebrovascular disease) are also rising. Traditional oral hypoglycaemic agents only partially prevent the development of these complications. This suggests that selective treatment options that target specific biological pathways (i.e. metabolic factors, intracellular signaling proteins and growth factors) may be a more effective strategy. Type 1 and Type 2 diabetic animal models have been produced spontaneously by selective inbreeding or by genetic modification, as well as, pharmacological induction. These models have become a safe and reliable option to test the therapeutic potential of novel drugs. They also help to understand the pathophysiology of diabetes mellitus. This review highlights the most commonly used animal models for the treatment of diabetic micro and macrovascular complications.
Keywords: Diabetes mellitus, animal models, microvascular complications, macrovascular complications
Current Pharmaceutical Design
Title: Animal Models of Diabetes Mellitus: Relevance to Vascular Complications
Volume: 14 Issue: 4
Author(s): Cecil S. Thompson
Affiliation:
Keywords: Diabetes mellitus, animal models, microvascular complications, macrovascular complications
Abstract: The prevalence of diabetes mellitus is increasing worldwide at an alarming rate due to population growth, obesity, sedentary lifestyle and aging. Consequently, diabetic microvascular complications (retinopathy and nephropathy) and macrovascular complications (coronary heart disease, peripheral arterial disease and cerebrovascular disease) are also rising. Traditional oral hypoglycaemic agents only partially prevent the development of these complications. This suggests that selective treatment options that target specific biological pathways (i.e. metabolic factors, intracellular signaling proteins and growth factors) may be a more effective strategy. Type 1 and Type 2 diabetic animal models have been produced spontaneously by selective inbreeding or by genetic modification, as well as, pharmacological induction. These models have become a safe and reliable option to test the therapeutic potential of novel drugs. They also help to understand the pathophysiology of diabetes mellitus. This review highlights the most commonly used animal models for the treatment of diabetic micro and macrovascular complications.
Export Options
About this article
Cite this article as:
Thompson S. Cecil, Animal Models of Diabetes Mellitus: Relevance to Vascular Complications, Current Pharmaceutical Design 2008; 14 (4) . https://dx.doi.org/10.2174/138161208783497679
DOI https://dx.doi.org/10.2174/138161208783497679 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Matrix Metalloproteinases: Drug Targets for Myocardial Infarction
Current Drug Targets The Role of Natural Killer T Cells in Atherosclerosis
Current Immunology Reviews (Discontinued) Recent Developments on Coronary Microvasculopathy after Heart Transplantation:A New Target in the Therapy of Cardiac Allograft Vasculopathy
Current Vascular Pharmacology Cardioprotective Potential of Iron Chelators and Prochelators
Current Medicinal Chemistry HCN Pacemaker Channels and Pain: A Drug Discovery Perspective
Current Pharmaceutical Design Patented Aptamers for C-Reactive Protein Detection: A Review About their Use in Clinical Diagnostics
Recent Patents on DNA & Gene Sequences Population-based Study of Risk Polymorphisms Associated with Vascular Disorders and Dementia
Current Genomics Heart Failure in North America
Current Cardiology Reviews Traditional Chinese Medicine - Sea Urchin
Mini-Reviews in Medicinal Chemistry High-Density Lipoprotein Quantity or Quality for Cardiovascular Prevention?
Current Pharmaceutical Design Efficacy and Safety of Evacetrapib for Modifying Plasma Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Current Pharmaceutical Design Editorial (Towards Better Understanding on Psychiatric Disorder, Ocular Diseases, Heart Disease and Cancer)
Current Molecular Medicine Joint ESC/EASD Guidelines on Diabetes, where are we Now and where should we Go?
Current Vascular Pharmacology Anti-Cancer, Pharmacokinetic and Biodistribution Studies of Cremophor EL Free Alternative Paclitaxel Formulation
Current Drug Safety Clinical Aspects and Therapeutic Perspectives of Relaxin
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Exploring and Prioritization of Mobile-Based Self-Management Strategies for HIV Care
Infectious Disorders - Drug Targets Lifestyle Modification with Physical Activity Promotion on Leptin Resistance and Quality of Life in Metabolic Syndrome - A Systematic Review with Meta-Analysis
Current Diabetes Reviews Treatment of Chronic Peripheral Arterial Disease
Current Vascular Pharmacology Comparison Between the Effects of Bupivacaine and Levobupivacaine for Spinal Anesthesia on QT Dispersion
Cardiovascular & Hematological Disorders-Drug Targets Epidemiology of Upper Gastrointestinal Damage Associated with Low-Dose Aspirin
Current Pharmaceutical Design